Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2022 filed with the SEC

September 1, 2022October 26, 2022 Alterity Therapeutics

XBRL 30 June 2022 filed with the SEC

Post navigation

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Related Posts

Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

November 7, 2022November 7, 2022

Prana EGM and Conference Call Facility

March 27, 2019August 16, 2022

Senior male researcher carrying out scientific research

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s

July 1, 2021August 16, 2022

Recent Posts

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
ShareCafe Investor Webinar Recording
ShareCafe Investor Webinar Presentation
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065